ImmunityBio data highlights highly individualized patient priorities in bladder cancer care
Share
ImmunityBio (NASDAQ:IBRX) announced new survey data highlighting the highly individualized treatment preferences and quality-of-life priorities of patients navigating high-risk non-muscle-invasive bladder cancer (NMIBC).
